Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 53,107 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Lantheus Trading Down 0.2 %

Shares of LNTH opened at $100.23 on Friday. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The stock has a market cap of $6.86 billion, a P/E ratio of 16.68 and a beta of 0.44. The company has a 50-day moving average of $90.29 and a two-hundred day moving average of $96.78.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the 3rd quarter worth about $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the 4th quarter worth about $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus during the fourth quarter worth about $37,000. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC purchased a new position in shares of Lantheus during the third quarter valued at approximately $60,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the topic of several research analyst reports. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.